Education and Training
- Hematology/Oncology Fellowship, Medicine, Duke University School of Medicine, 2014 - 2017
- Internal Medicine Residency, Indiana University School of Medicine, 2011 - 2014
- D.O., University of New England, 2011
Force, J, Howie, LJ, Abbott, SE, Bentley, R, Marcom, PK, Kimmick, G, Westbrook, K, Sammons, SL, Parks, M, Topping, DL, Emerson, R, Broadwater, G, Hyslop, T, Blackwell, KL, and Nair, SK. "Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype." Clinical Breast Cancer 18, no. 5 (October 2018): 410-417.
Ong, CT, Campbell, BM, Thomas, SM, Greenup, RA, Plichta, JK, Rosenberger, LH, Force, J, Hall, A, Hyslop, T, Hwang, ES, and Fayanju, OM. "Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database." Annals of Surgical Oncology 25, no. 8 (August 2018): 2249-2260.
Thomas, SM, Fayanju, OM, Plichta, JK, Rosenberger, LH, Force, J, Hyslop, T, Hwang, ES, and Greenup, RA. "Treatment Patterns and Outcomes for Breast Cancer with Isolated Supraclavicular Metastases." 71st Annual Cancer Symposium of the Society-of-Surgical-Oncology. Chicago, IL. March 21, 2018 - March 24, 2018.: SPRINGER, February 1, 2018.
Ong, CT, Thomas, SM, Campbell, BM, Greenup, RA, Plichta, JK, Rosenberger, LH, Force, JM, Hyslop, T, Hwang, E-SS, and Fayanju, OM. "A population-based analysis of treatment and outcomes in 2,500 meta plastic breast cancer patients." May 20, 2017.
Campbell, BM, Thomas, SM, Ong, CT, Greenup, RA, Plichta, JK, Rosenberger, LH, Force, JM, Hyslop, T, Hwang, E-SS, and Fayanju, OM. "The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database." May 20, 2017.
Force, J, Abbott, S, Broadwater, G, Kimmick, G, Westbrook, K, Hwang, S, Kauff, N, Stashko, I, Weinhold, K, Nair, S, Hyslop, T, Blackwell, K, Castellar, E, and Marcom, P. "Abstract P2-04-19: Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients." February 15, 2017.
Force, J, and Salama, AK. "First-line treatment of metastatic melanoma: role of nivolumab." ImmunoTargets and therapy 6 (January 2017): 1-10. (Review)
Spiegel, D, Marcom, PK, Peterson, B, Force, J, Howie, L, Palta, M, Blitzblau, RC, and Horton, JK. "Acute Toxicity in Patients With HER2-Positive Breast Cancer Treated With Adjuvant Radiation Therapy and Concurrent Trastuzumab and Pertuzumab." International journal of radiation oncology, biology, physics 96, no. 2S (October 2016): E9-E10.
Force, JM, Howie, LJ, Abbottt, S, Bentley, RC, Marcom, PK, Kimmick, GG, Westbrook, KE, Parks, M, Topping, DL, Broadwater, G, Blackwell, KL, and Nair, SK. "Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens." May 20, 2016.
Howie, L, Marcom, P, Topping, D, Force, J, Emerson, R, Bhavsar, N, Abbott, S, Parks, M, Robins, H, and Blackwell, K. "Abstract P4-14-16: T-cell clonality increases after neoadjuvant treatment with trastuzumab and pertuzumab." February 15, 2016.